mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

Yasuno Masamichi; Uetake Hiroyuki; Ishiguro Megumi; Mizunuma Nobuyuki; Komori Takamichi; Miyata Go; Shiomi Akio; Kagimura Tatsuo; Sugihara Kenichi

首页> 外文期刊>International journal of clinical oncology >mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

【24h】

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

机译：Mfolfox6加上贝伐单抗治疗肝脏癌的肝脏转移，这些癌症不适合前期切除（TRICC0808）：包括最终存活的最终分析的多中心期II试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background The TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015).

机译：背景技术TRICC0808试验是II期多制制试验，研究了术前MfolfoX6 + Bevacizumab（BV）治疗对肝脏转移的疗效，这是不适合前期切除的肝脏转移。据报道，疗效分析中的R0切除率为44.4％，进行了存活的最终分析（2015年2月16日的数据固定）。

著录项

来源
《International journal of clinical oncology》 |2019年第5期|共10页
作者
Yasuno Masamichi; Uetake Hiroyuki; Ishiguro Megumi; Mizunuma Nobuyuki; Komori Takamichi; Miyata Go; Shiomi Akio; Kagimura Tatsuo; Sugihara Kenichi;
展开▼
作者单位

Tokyo Med &

Dent Univ Inst Global Affairs Bunkyo Ku 1-5-45 Yushima Tokyo 1138519 Japan;

Tokyo Med &

Dent Univ Grad Sch Dept Specialized Surg Bunkyo Ku 1-5-45 Yushima Tokyo 1138519;

Tokyo Med &

Dent Univ Grad Sch Dept Specialized Surg Bunkyo Ku 1-5-45 Yushima Tokyo 1138519;

Japanese Fdn Canc Res Canc Inst Hosp Dept Med Oncol Koto Ku 3-8-31 Ariake Tokyo 1358550 Japan;

Osaka Gen Med Ctr Dept Surg 3-1-56 Bandai Higashi Sumiyoshi Osaka 5588558 Japan;

Iwate Prefectural Cent Hosp Dept Surg 1-4-1 Ueda Morioka Iwate 0200066 Japan;

Shizuoka Canc Ctr Colon &

Rectal Surg 1007 Shimonogakubo Shunto Shuzuoka 4118777 Japan;

Translat Res Informat Ctr Dept Stat Anal Chou Ku 1-5-4 Minatojima Minamimachi Kobe Hyogo;

Tokyo Med &

Dent Univ Grad Sch 1-5-45 Yushima Tokyo 1138519 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Liver metastases; Colorectal cancer; Initially resectable; Initially unresectable; Hepatectomy;

机译：肝转移;结肠直肠癌;最初可重新切转;最初不可切除;肝切除术;

相似文献

外文文献
中文文献
专利

1. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival [J] . Yasuno Masamichi, Uetake Hiroyuki, Ishiguro Megumi, International journal of clinical oncology . 2019,第5期

机译：Mfolfox6加上贝伐单抗治疗肝脏癌的肝脏转移，这些癌症不适合前期切除（TRICC0808）：包括最终存活的最终分析的多中心期II试验
2. 6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection [J] . R.Wong, C.Saffery, Y.Barbachano, European Journal of Cancer Supplements . 2009,第2期

机译：6076 BOXER：卡培他滨和奥沙利铂联合贝伐单抗的多中心II期试验作为新辅助治疗不适合前期切除的结直肠癌仅肝转移的患者
3. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection [J] . A Dewdney, D Cunningham, Y Barbachano, British Journal of Cancer . 2012,第11期

机译：BOXER研究（卡培他滨，奥沙利铂（CAPOX）+贝伐珠单抗作为围手术期治疗的II期临床研究）在45例低危结直肠仅肝转移患者中不适合进行前期切除术
4. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival [O] . Masamichi Yasuno, Hiroyuki Uetake, Megumi Ishiguro, -1

机译：mFOLFOX6加上贝伐单抗用于治疗不适合前期切除的仅结直肠癌的仅肝转移灶（TRICC0808）：一项多中心II期临床试验包括最终生存期分析
5. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival [O] . Masamichi Yasuno, Hiroyuki Uetake, Megumi Ishiguro, 2019

机译：MfolfoX6加上贝伐单抗治疗肝脏癌的肝脏转移，这些癌症不适合前期切除（TRICC0808）：多中心期II试验，包括存活的最终分析

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

摘要

著录项

相似文献

相关主题

期刊订阅